AlphAIAlphAI — Financial news for AI agents
news.jkn.co.krOCT 294 min read$LLY

Eli Lilly Shares Jump 6.6% as Mounjaro and Zepbound Fuel Third-Quarter Earnings Beat

Eli Lilly reported Q3 revenue of $24.4B, up 39% YoY, beating estimates. Mounjaro and Zepbound sales exceeded expectations, while Foundayo fell short. The company raised its 2026 revenue guidance to $91B-$92B. Shares rose 6.63% on the news.

Original reporting
news.jkn.co.kr
Published Oct 29, 2026, 8:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Eli Lilly Shares Jump 6.6% as Mounjaro and Zepbound Fuel Third-Quarter Earnings Beat — source image
Source · news.jkn.co.kr
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

The quarter’s beat and raised FY2026 revenue outlook are the primary drivers for repricing. The article also provides product-level sales growth and a competitive share snapshot versus Novo Nordisk, which can influence forward demand assumptions.

02

Market read

This is a direct earnings-and-guidance update for a major GLP-1 franchise, with same-day stock reaction and explicit FY2026 targets.

03

What to watch

Realized price declines (15% down) partially offset volume growth, so upside may depend on whether pricing stabilizes while volume continues to scale.

Relevance 9/10Novelty 9/10Timing: post-market reaction on Oct. 29, with guidance update for FY2026

Background

Lilly’s metabolic franchise is centered on injectable GLP-1/GIP therapies (Mounjaro for diabetes, Zepbound for obesity) and an emerging oral GLP-1 weight-loss product (Foundayo).

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q3 revenue and EPS beats and raised full-year 2026 revenue guidance, driven by Mounjaro and Zepbound demand.

Expected impact

Likely further upward pressure as traders reprice full-year growth expectations around Mounjaro and Zepbound, offset slightly by the weaker Foundayo launch.

Evidence & confidence

The article cites specific Q3 beat metrics and a higher full-year revenue range, which are direct inputs to near-term valuation and estimates. It also flags Foundayo underperforming forecasts, a secondary negative for mix/trajectory.

Market effects

Sector

Reinforces bullish read-through for GLP-1 obesity/diabetes demand and competitive share dynamics in metabolic drugs.

Regional

Supports US large-cap pharma sentiment, potentially lifting peers with GLP-1 exposure via sentiment and estimate revisions.

Global

Signals sustained global demand strength for incretin-based therapies, relevant to international obesity/diabetes treatment markets.

Counterpoint

What could challenge this read

The Foundayo oral GLP-1 miss versus forecasts could indicate slower-than-expected adoption for the next product cycle, limiting how far the multiple can expand.

Key entities

  • company
    Eli Lilly

    Reported Q3 results above estimates and raised FY2026 revenue and non-GAAP EPS guidance, citing strong Mounjaro and Zepbound demand.

  • product
    Mounjaro

    Type 2 diabetes drug; Q3 revenue rose 65% to $10.72B, above expectations.

  • product
    Zepbound

    Obesity drug; Q3 sales rose 49% to $5.35B, above expectations.

  • product
    Foundayo

    New oral GLP-1 weight-loss pill; Q3 revenue of $184M missed forecasts.

  • company
    Novo Nordisk

    Rival cited for US obesity and diabetes market share comparison (36.6% vs Lilly’s 63%).

Read at source← All news

StoryEli Lilly beats Q3 earnings, lifts full‑year revenue outlook and trims EPS guidance

Also covered by

4 outlets

Related articles

OCT 29
$GOOGLMedAI 8/10

Alphabet's AI Spending Shock Drags Nasdaq Down 1.7% as Wall Street's Big Three Retreat

Alphabet's shares fell 13.2% after its quarterly report missed revenue forecasts and showed increased AI spending, dragging the Nasdaq down 1.7%. The S&P 500 and Dow Jones also declined. Investors are differentiating between companies funding AI internally and those relying on debt or cash burn. Other notable movers include Caterpillar (-9.5%), Fortinet (-20%), and Eli Lilly (+6.3%).

finance.biggo.com6 min
OCT 29
$LLYHighAI 9/10

Lilly Raises 2026 Revenue Outlook as Mounjaro, Zepbound Sales Rise

Eli Lilly raised its 2026 revenue outlook to $91B-$92B due to strong sales of Mounjaro and Zepbound, reporting Q3 revenue of $24.4B, up 38% YoY. Mounjaro revenue grew 65% to $10.7B, while Zepbound grew 49% to $5.35B. Non-GAAP EPS was $7.48, up 7% YoY. Lilly cited acquisition-related charges for a slight EPS forecast reduction.

econotimes.com5 min
OCT 29
$LLYMedAI 8/10

Eli Lilly and Company Q3 2026 Earnings Call Summary

Eli Lilly reported Q3 2026 revenue growth of 39%, driven by Mounjaro, Zepbound, and oncology/immunology/neuroscience portfolios. Full-year guidance raised to $91-$92B. Management highlighted Medicare GLP-1 bridge program success, international expansion, and investments in manufacturing and R&D. Non-recurring items added $900M to Q3 revenue, with $2B expected for 2026. Strategic shifts include global market restructuring and pipeline advancements in Alzheimer's and obesity treatments.

finance.yahoo.com7 min
OCT 29
$LLYHighAI 9/10

Eli Lilly (LLY) Q3 2026 Earnings Call Transcript

Eli Lilly (LLY) reported Q3 2026 revenue of $24.4B, up 39% YoY, driven by Mounjaro and Zepbound. Non-GAAP EPS was $7.48. FY 2026 guidance raised to $91B-$92B. Key growth areas include obesity and diabetes treatments, with strong international demand. The company invested in manufacturing and R&D, facing pricing pressures offset by volume growth.

fool.com3 min
OCT 29
$LLYHighAI 9/10

Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction

Eli Lilly (LLY) reported Q3 revenue of $24.4B, up 39% YoY, driven by 53% volume growth despite a 15% price drop. Shares rose 6% midday. Management raised 2026 revenue guidance to $91B-$92B. Gross margin increased to 83.9%, and GAAP EPS rose 16% to $7.22. Growth was fueled by Mounjaro and Zepbound, which generated two-thirds of revenue.

finance.yahoo.com2 min